NEW YORK (GenomeWeb News) – Quidel has received US Food and Drug Administration 510(k) clearance to market its molecular respiratory viral panel in the US, the company said on Tuesday.

The assay, called the Quidel Molecular RSV + hMPV assay, detects respiratory syncytial virus and human metapneumovirus and distinguishes the two from each other. While they are different viruses, they cause respiratory infections with very similar symptoms, Quidel said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.